Idera Announces Leadership Appointments
January 26 2015 - 4:30PM
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage
biopharmaceutical company developing immune-modulating and gene
silencing therapies for cancer and rare diseases, today announced
the appointments of R. Clayton Fletcher as Senior Vice President,
Business Development and Strategic Planning, and Jim Baker as
Executive Director, Market Development.
Vincent J. Milano, President and Chief Executive Officer of
Idera Pharmaceuticals, stated, "We are delighted to welcome Clayton
to Idera. His business acumen and strategic insight forged over 25
years in the biopharmaceutical industry will significantly enhance
our ability to grow our business and deliver potential therapeutic
solutions to patients suffering from life-threatening
diseases."
In his new role, Mr. Fletcher will oversee business development
and corporate strategy. Mr. Fletcher most recently served as Vice
President, Business Development and Project Management at
ViroPharma Incorporated from June 2005 until January 2014. In this
capacity, Mr. Fletcher played a central role in the acquisition,
in-licensing and out-licensing of several major biopharmaceutical
assets. Prior to joining ViroPharma in 2001, Mr. Fletcher held
business and scientific roles of increasing responsibility at
SmithKline Beecham Pharmaceuticals, Becton-Dickson and Company,
Intracel Corporation and Centocor. He received B.S. and M.S.
degrees in biology from Wake Forest University.
Mr. Milano added, "We are also pleased to announce Jim's new
position with the company. In recent months, he has made important
contributions toward advancing our business. Moving forward, he
will focus on building and expanding relationships with key opinion
leaders and patient advocacy groups, based on his market
development experience across multiple rare disease
categories."
Mr. Baker joined Idera in August 2014 and most recently served
as Executive Director, Corporate Affairs. In his new role, Mr.
Baker will oversee awareness and education initiatives, alliance
development and market insight assessment across the company's
cancer and rare disease development programs. Prior to joining
Idera, Mr. Baker held roles of increasing responsibility focused on
marketing communications, scientific and medical communications,
advocacy relations and public affairs at PTC Therapeutics, Biogen
Idec and Sarepta Therapeutics. He is a former communications
officer in the U.S. Army and holds B.A. degrees in journalism and
political science from the University of Southern California.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage, patient-focused
biopharmaceutical company developing novel therapeutic approaches
for the treatment of cancer and rare diseases. Our proprietary
technology platforms are based on the company's scientific
expertise with nucleic acid therapeutics. Idera's immunotherapy
approach is based on the modulation of Toll-like receptors (TLRs),
which have key roles in the immune system. In addition, we are
developing gene silencing oligonucleotides (GSOs), a third
generation antisense technology, to inhibit the production of
disease-associated proteins by targeting RNA. To learn more about
Idera, visit www.iderapharma.com.
Inducement Grant Under NASDAQ Listing Rule
5635(c)(4)
In connection with the hiring of Mr. Fletcher, the Board of
Directors of the Company approved the grant to Mr. Fletcher of a
stock option to purchase 600,000 shares of the Company's common
stock. The option was granted as an inducement equity award outside
the Company's 2013 Stock Incentive Plan and was made as an
inducement material to Mr. Fletcher's acceptance of employment with
the Company. The option will have an exercise price equal to the
closing price of the Company's common stock on January 26, 2015.
The option has a ten year term and vests over four years, with 25%
of the original number of shares vesting on January 26, 2016 and an
additional 6.25% of the original number of shares vesting at the
end of each successive quarter thereafter, subject to Mr.
Fletcher's continued service with the Company through the
applicable vesting dates.
CONTACT: Investor and Media Contact
Robert Doody
Vice President,
Investor Relations and Corporate Communications
484-639-7235
rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024